Podcast Episodes
Back to Search
Ep. 346 - 2026 Public Markets Preview
Season 7 Episode 346
The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the Bi…
7 months, 2 weeks ago
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
Season 7 Episode 345
Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podc…
7 months, 2 weeks ago
Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
Season 7 Episode 344
The J.P. Morgan Healthcare Conference kicked off this week with sunny skies over San Francisco and more financial momentum than the biotech industry …
7 months, 3 weeks ago
Ep. 343 - JPM Deals, Policy Outlook, Approval Trends
Season 7 Episode 343
Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital raised a…
7 months, 3 weeks ago
Ep. 342 - 2026 Biotech Kickoff
Season 7 Episode 342
The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun to churn …
8 months ago
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
Season 6 Episode 341
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and …
8 months, 1 week ago
Ep. 340 - Obesity Data, Kymera & FDA Survey Results
Season 6 Episode 340
Obesity readouts continue to be hot for biotech with new top-line data from both injectable and oral therapies pushing the boundaries on efficacy. On…
8 months, 3 weeks ago
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Season 6 Episode 339
Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go…
9 months ago
Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding
Season 6 Episode 338
Novo Nordisk’s highly anticipated data for semaglutide in Alzheimer’s dashed hopes that the GLP-1 therapy could become a game changer in the disease.…
9 months, 1 week ago
Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc
Season 6 Episode 337
A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the latest example…
9 months, 2 weeks ago